tetano
Editor, Senior Moderator
PLoS One. 2015 Jul 1;10(7):e0129712. doi: 10.1371/journal.pone.0129712. eCollection 2015.
[h=1]Life-Threatening Abnormal Behavior Incidence in 10-19 Year Old Patients Administered Neuraminidase Inhibitors.[/h] Nakamura Y[SUP]1[/SUP], Sugawara T[SUP]2[/SUP], Ohkusa Y[SUP]2[/SUP], Taniguchi K[SUP]3[/SUP], Miyazaki C[SUP]4[/SUP], Momoi M[SUP]5[/SUP], Okabe N[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Much discussion has surrounded the association between the administration of neuraminidase inhibitors (NI) and severe abnormal behaviors, including sudden running away and jumping from a high place, which can be life-threatening if no one intervenes. Using data on the number of abnormal behaviors and patients who had been prescribed NI in Japan, we calculated the incidence rate of severe abnormal behaviors among influenza patients who had been prescribed NI. Then, we evaluated the relative risk between the four types of NI on severe abnormal behavior. We found no significant difference in the incidence rates of abnormal behavior by the type of NI. Results implicate that the current policy of package inserts, which warn physicians that patients who were administered ANY type of NI might exhibit abnormal behavior, seems to be appropriate.
PMID: 26132729 [PubMed - in process] Free full text
[h=1]Life-Threatening Abnormal Behavior Incidence in 10-19 Year Old Patients Administered Neuraminidase Inhibitors.[/h] Nakamura Y[SUP]1[/SUP], Sugawara T[SUP]2[/SUP], Ohkusa Y[SUP]2[/SUP], Taniguchi K[SUP]3[/SUP], Miyazaki C[SUP]4[/SUP], Momoi M[SUP]5[/SUP], Okabe N[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Much discussion has surrounded the association between the administration of neuraminidase inhibitors (NI) and severe abnormal behaviors, including sudden running away and jumping from a high place, which can be life-threatening if no one intervenes. Using data on the number of abnormal behaviors and patients who had been prescribed NI in Japan, we calculated the incidence rate of severe abnormal behaviors among influenza patients who had been prescribed NI. Then, we evaluated the relative risk between the four types of NI on severe abnormal behavior. We found no significant difference in the incidence rates of abnormal behavior by the type of NI. Results implicate that the current policy of package inserts, which warn physicians that patients who were administered ANY type of NI might exhibit abnormal behavior, seems to be appropriate.
PMID: 26132729 [PubMed - in process] Free full text